GenEdit

South San Francisco, United States

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

$24.0M raised

Jan 2024

Series A

Top Investors

National Science FoundationSequoia CapitalEli LillyQiming Venture PartnersDCVC Bio

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has GenEdit raised?

GenEdit has raised $24.0M in total funding. The most recent round was Series A. The last funding was announced in January 2024.

Who are GenEdit's investors?

GenEdit's investors include National Science Foundation, Sequoia Capital, Eli Lilly, Qiming Venture Partners, DCVC Bio.

Where is GenEdit headquartered?

GenEdit is headquartered in South San Francisco, United States.

What does GenEdit do?

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

What stage is GenEdit at?

GenEdit is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 23, 2024.

MLA

"GenEdit — Funding & Investors." VCBacked, January 23, 2024, https://www.vcbacked.co/company/genedit. Accessed June 4, 2026.

APA

VCBacked. (2024). GenEdit — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/genedit

Wikipedia (cite web)

{{cite web |title=GenEdit — Funding & Investors |url=https://www.vcbacked.co/company/genedit |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 23, 2024.